Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김명 | * |
dc.contributor.author | 류호영 | * |
dc.date.accessioned | 2021-08-12T16:32:51Z | - |
dc.date.available | 2021-08-12T16:32:51Z | - |
dc.date.issued | 2021 | * |
dc.identifier.issn | 0724-4983 | * |
dc.identifier.other | OAK-29734 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/258908 | - |
dc.description.abstract | Objective: To identify patients who can safely evade the magnetic resonance imaging fusion-targeted biopsy (MRIFTB) for prostate imaging reporting and data system (PI-RADS) 3 lesion. Materials and methods: Overall, 755 men with PI-RADS 3–5 lesions who underwent MRIFTB were retrospectively analyzed. Univariate and multivariate analyses were performed to determine significant predictors for clinically significant prostate cancer (CSPCa), defined as Gleason grade group ≥ II. Detection rates and negative predictive values of CSPCa were estimated according to various clinical settings. Results: Median age, prostate-specific antigen (PSA), and PSA density of patients were 66.0 years, 7.39 ng/mL, and 0.19 ng/mL, respectively. Overall detection rates of CSPCa according to PI-RADS 3 (n = 347), 4 (n = 260), and 5 (n = 148) lesions were 15.0%, 30.4%, and 80.4%, respectively. The negative predictive value (NPV) of PI-RADS 3 lesion on MRI was 15.0%. On multivariate analysis, age [≥ 65 years, odds ratio (OR) = 0.427], PSA density (≥ 0.20 ng/mL2, OR = 0.234), prior negative biopsy history (OR = 2.231), and PI-RADS score (4, OR = 0.427; 5, OR = 0.071) were independent predictors for the absence of CSPCa by MRIFTB. When assessed according to various conditions, NPVs of PI-RADS 3 lesions were relatively high in subgroups with low PSA density (< 0.20 ng/mL2) regardless of age or prior biopsy history (NPV range 91.1–91.9%). Contrarily, NPVs in subgroups with high PSA density were relatively low and varied according to age or prior biopsy history groups (NPV range 50.0–86.8%). Conclusions: Men with the PI-RADS 3 lesion and low PSA density might safely evade the MRIFTB, regardless of age or prior biopsy history. © 2020, Springer-Verlag GmbH Germany, part of Springer Nature. | * |
dc.language | English | * |
dc.publisher | Springer Science and Business Media Deutschland GmbH | * |
dc.subject | Biopsy | * |
dc.subject | Detection | * |
dc.subject | Magnetic resonance imaging | * |
dc.subject | Prostate cancer | * |
dc.subject | Prostate-specific antigen | * |
dc.subject | Screening | * |
dc.title | Who can safely evade a magnetic resonance imaging fusion-targeted biopsy (MRIFTB) for prostate imaging reporting and data system (PI-RADS) 3 lesion? | * |
dc.type | Article | * |
dc.relation.issue | 5 | * |
dc.relation.volume | 39 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 1463 | * |
dc.relation.lastpage | 1471 | * |
dc.relation.journaltitle | World Journal of Urology | * |
dc.identifier.doi | 10.1007/s00345-020-03352-3 | * |
dc.identifier.scopusid | 2-s2.0-85088239522 | * |
dc.author.google | Kim M. | * |
dc.author.google | Ryu H. | * |
dc.author.google | Lee H.J. | * |
dc.author.google | Hwang S.I. | * |
dc.author.google | Choe G. | * |
dc.author.google | Hong S.K. | * |
dc.contributor.scopusid | 류호영(57204212724) | * |
dc.date.modifydate | 20240315113419 | * |